Business Description
SELLAS Life Sciences Group Inc
NAICS : 325412
SIC : 2834
ISIN : US81642T2096
Total Employee Number:
13Description
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 122.96 | |||||
Equity-to-Asset | 0.94 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.03 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 4/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 46 | |||||
3-Year EPS without NRI Growth Rate | 46.5 | |||||
3-Year FCF Growth Rate | 43.7 | |||||
3-Year Book Growth Rate | 26.1 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 48.82 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 73.73 | |||||
9-Day RSI | 74.23 | |||||
14-Day RSI | 73.04 | |||||
3-1 Month Momentum % | 101.69 | |||||
6-1 Month Momentum % | 91.49 | |||||
12-1 Month Momentum % | 292.92 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 17.22 | |||||
Quick Ratio | 17.22 | |||||
Cash Ratio | 16.59 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -93.9 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -53.01 | |||||
ROA % | -47.31 | |||||
ROIC % | -685.53 | |||||
3-Year ROIIC % | 773.89 | |||||
ROC (Joel Greenblatt) % | -4089.29 | |||||
ROCE % | -56.37 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 25.3 | |||||
Price-to-Tangible-Book | 25.82 | |||||
EV-to-EBIT | -90.21 | |||||
EV-to-EBITDA | -90.21 | |||||
EV-to-Forward-Revenue | 11.15 | |||||
EV-to-FCF | -100.78 | |||||
| Price-to-Net-Current-Asset-Value | 25.82 | |||||
| Price-to-Net-Cash | 27.23 | |||||
Earnings Yield (Greenblatt) % | -1.11 | |||||
FCF Yield % | -0.96 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:SLS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
SELLAS Life Sciences Group Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.23 | ||
| Beta | 1.4355 | ||
| 3-Year Sharpe Ratio | 0.89 | ||
| 3-Year Sortino Ratio | 2.33 | ||
| Volatility % | 164.62 | ||
| 14-Day RSI | 73.04 | ||
| 14-Day ATR ($) | 1.284358 | ||
| 20-Day SMA ($) | 9.744 | ||
| 12-1 Month Momentum % | 292.92 | ||
| 52-Week Range ($) | 1.39 - 15.8765 | ||
| Shares Outstanding (Mil) | 196.63 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
SELLAS Life Sciences Group Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
SELLAS Life Sciences Group Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-12 | In 130 days | ||
| Second quarter earnings results for 2026 | 2026-08-12 | In 38 days | ||
| General meeting for 2026 | 2026-06-17 08:30 | 7.53 (-0.92%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 5.25 (+4.79%) | ||
| Annual report for 2025 | 2026-03-19 | 4.95 (-1.20%) | ||
| Fourth quarter earnings results for 2026 | 2026-03-19 | 4.95 (-1.20%) | ||
| Third quarter earnings results for 2025 | 2025-11-12 | 1.51 (+0.67%) | ||
| Second quarter earnings results for 2025 | 2025-08-12 | 1.54 (-3.75%) | ||
| General meeting for 2025 | 2025-06-17 08:30 | 1.61 (-5.85%) | ||
| A.G.P. Virtual Healthcare Company Showcase | 2025-05-21 08:20 | 1.94 (+7.18%) |
Show
Entries
SELLAS Life Sciences Group Inc Frequently Asked Questions
What is SELLAS Life Sciences Group Inc(SLS)'s stock price today?
The current price of SLS is $14.98. The 52 week high of SLS is $15.88 and 52 week low is $1.39.
When is next earnings date of SELLAS Life Sciences Group Inc(SLS)?
The next earnings date of SELLAS Life Sciences Group Inc(SLS) is 2026-08-12 Est..
Does SELLAS Life Sciences Group Inc(SLS) pay dividends? If so, how much?
SELLAS Life Sciences Group Inc(SLS) does not pay dividend.
Guru Commentaries on NAS:SLS
No articles.
Press Release
Articles on SELLAS Life Sciences Group Inc
No articles.
Headlines
See More- 1
Jul 01, 2026
Most and least shorted mid- to mega-cap healthcare stocks at the end of June
Seeking Alpha • 9:05am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers